BioCentury
ARTICLE | Clinical News

Acelarin: Phase I/II final data

June 8, 2015 7:00 AM UTC

Final data from an open-label, U.K. Phase I/II trial in 49 evaluable patients with advanced solid tumors showed that IV Acelarin led to a disease control rate (DCR) of 78%, including 5 partial respons...